As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...

Sanofi is set to acquire DR-0201 from Dren Bio for up to $1.9 billion, aiming to expand its autoimmune disease pipeline with ...

The drug leads to depletion of these cells via phagocytosis, a process in which ... The Dren Bio drug is currently being evaluated in two Phase 1 studies, one in healthy volunteers and the other ...

DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing ...

Sanofi has announced that it will be broadening its immunology pipeline by acquiring Dren Bio’s phase 1 CD20-directed ...

Sanofi to pay $600 million upfront payment to buy Dren Bio's bispecific myeloid cell engager, DR-0201: Paris Friday, March 21, 2025, 09:00 Hrs [IST] Sanofi and Dren Bio, Inc., a p ...

Sanofi and Dren Bio, Inc., a private clinical-stage biopharmaceutical company, have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid ...

Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio Inc. for $600 million upfront ...

ES019 is still in preclinical development, but, according to Astellas, has shown evidence that it can stimulate “highly potent” phagocytosis ... pack – failed a phase 3 trial in ...